Filtered By:
Condition: Pneumonia
Infectious Disease: Influenza
This page shows you your search results in order of date.
Order by Relevance | Date
Total 36 results found since Jan 2013.
AI Cough-Monitoring Can Change the Way We Diagnose Disease
How many times do you cough a day? Do you cough more when you’re indoors or outside? Or more often after you eat? Or at night?
Chances are, your cough memory might not be that accurate. But all of that information about your coughing patterns could be an untapped resource to better understand your health. Coughs may be benign ways to clear a little extra phlegm, or they could be early signs of more serious conditions such as asthma, GERD (gastroesophageal reflux disease), or even lung cancer.
“In the era of precision health, it’s ironic that such a problematic symptom is simply unmeasured,” says Pet...
Source: TIME: Health - April 3, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized healthscienceclimate Technology Source Type: news
Janssen Announces Phase 2b Data Demonstrating its Investigational RSV Adult Vaccine Provided 80% Protection against Lower Respiratory Infections in Older Adults
RARITAN, N.J., October 2, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that its investigational respiratory syncytial virus (RSV) vaccine candidate was highly effective in protecting against lower respiratory tract disease (LRTD) caused by RSV, demonstrating vaccine efficacy of 80 percent (CI, 52.2-92.9%) in adults aged 65 and older. The study results were presented as a late-breaking abstract at the virtual IDWeek 2021 conference on October 2.“The findings from our CYPRESS study are very encouraging as we seek to deliver a long-awaited preventive vaccine to stave off the severe ...
Source: Johnson and Johnson - October 2, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Announces Start of Phase 3 Trial for Investigational Respiratory Syncytial Virus (RSV) Vaccine in Older Adults
RARITAN, N.J., September 29, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the initiation of its Phase 3 EVERGREEN study. The study will evaluate the efficacy, safety and immunogenicity of Janssen’s investigational adult vaccine against lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV), when compared with placebo in approximately 23,000 adults aged 60 years and older throughout North America and a selection of countries across Europe, Asia and the Southern Hemisphere.The EVERGREEN study was initiated based on positive results from the Phase 2b CYPR...
Source: Johnson and Johnson - September 29, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Safety and effectiveness of dose-sparing strategies for intramuscular seasonal influenza vaccine: a rapid scoping review
Conclusions
Due to the low number of studies in healthy adults and the lack of studies assessing confirmed influenza and influenza-like illness, there remains a need for further evaluation.
Source: BMJ Open - September 17, 2021 Category: General Medicine Authors: Lunny, C., Antony, J., Rios, P., Williams, C., Ramkissoon, N., Straus, S. E., Tricco, A. C. Tags: Open access, Immunology (including allergy), COVID-19 Source Type: research
Study unravels antibiotic resistance in MRSA ‘superbug’ infections
FINDINGSResearchers applied a new approach pioneered at UCLA to predict whichmethicillin-resistant Staphylococcus aureus, or MRSA,infections willfail to respond toantibiotic treatment. By focusing on epigenetics — changes to gene expression that can’t be detected by standard DNA sequencing — the study examined how the immune system recognizes dangerous superbugs and works with antibiotics to clear them.BACKGROUNDThe Staphylococcus aureus bacterium can live harmlessly on a person’s skin and in their nose, occasionally causing mild infections that can be treated with standard antibiotics. When itentersthe bloodstre...
Source: UCLA Newsroom: Health Sciences - March 3, 2021 Category: Universities & Medical Training Source Type: news
Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial
NEW BRUNSWICK, N.J., January 29, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced topline efficacy and safety data from the Phase 3
ENSEMBLE
clinical trial, demonstrating that the investigational single-dose COVID-19 vaccine in development at its Janssen Pharmaceutical Companies met all primary and key secondary endpoints. The topline safety and efficacy data are based on 43,783 participants accruing 468 symptomatic cases of COVID-19. The Phase 3 ENSEMBLE study is designed to evaluate the efficacy and safety of the Janssen COVID-19 vaccine candidate in protecting moderate to severe COVID-...
Source: Johnson and Johnson - January 29, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Moderna ’s COVID-19 Vaccine Is 94.5% Effective. Here’s What That Really Means
It’s wasn’t a typical Sunday morning for Dr. Stephen Hoge, president of the biotech company Moderna, and Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases. They were at their respective homes in Massachusetts and Washington, D.C., waiting to to be let into a Zoom call to hear the results of the very first COVID-19 vaccine that was tested in people.
The hosts were members of the independent Data Safety Monitoring Board (DSMB) that is reviewing data involving all the COVID-19 vaccine candidates supported by the U.S. government’s Operation Warp Speed program, and Hoge a...
Source: TIME: Health - November 17, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
M238 evolving hypogammaglobulinemia: can chronic steroid exposure alter the course of hypogammaglobulinemia?
A seven-year-old boy presented to Allergy/Immunology for evaluation of hypogammaglobulinemia detected during pulmonary work-up of bronchiectasis. He had a history of asthma and recurrent pneumonia but no recurrent gastrointestinal or skin infections. Family history was non-contributory. IgG was 477 mg/dL (608-1229 mg/dL). IgA, IgM, and IgE levels were normal. Cystic fibrosis molecular testing was normal. Initial bronchoalveolar lavage grew H. influenza. Spirometry indicated mixed restrictive and obstructive patterns.
Source: Annals of Allergy, Asthma and Immunology - November 1, 2020 Category: Allergy & Immunology Authors: A. Navard-Keck, P. Varshney Source Type: research
How Remdesivir Moved From Back Shelf to Best Hope for Treating COVID-19
This study showed that a five-day regimen is as effective as 10 days–that’s important, doctors say, since it could mean shorter stays in the hospital, which could alleviate some of the burden on the health care system. “Of course we will have to wait for the final review of all the data, but it would be very nice to have an anti-viral that’s efficacious in this terrible illness,” says Dr. Aruna Subramanian, a clinical professor of medicine at Stanford and an investigator on the study. “At least we know that we can help patients with this, and that’s really the bottom line.”
T...
Source: TIME: Health - May 21, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 feature Magazine Source Type: news
Vaccines, Antibodies and Drug Libraries. The Possible COVID-19 Treatments Researchers Are Excited About
In early April, about four months after a new, highly infectious coronavirus was first identified in China, an international group of scientists reported encouraging results from a study of an experimental drug for treating the viral disease known as COVID-19.
It was a small study, reported in the New England Journal of Medicine, but showed that remdesivir, an unapproved drug that was originally developed to fight Ebola, helped 68% of patients with severe breathing problems due to COVID-19 to improve; 60% of those who relied on a ventilator to breathe and took the drug were able to wean themselves off the machines after 18...
Source: TIME: Health - April 14, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
All Your Coronavirus Questions, Answered
One of the worst symptoms of any plague is uncertainty—who it will strike, when it will end, why it began. Merely understanding a pandemic does not stop it, but an informed public can help curb its impact and slow its spread. It can also provide a certain ease of mind in a decidedly uneasy time. Here are some of the most frequently asked questions about the COVID-19 pandemic from TIME’s readers, along with the best and most current answers science can provide.
A note about our sourcing: While there are many, many studies underway investigating COVID-19 and SARS-CoV-19, the novel coronavirus that causes the illn...
Source: TIME: Health - April 14, 2020 Category: Consumer Health News Authors: TIME Staff Tags: Uncategorized COVID-19 Explainer Source Type: news
President Trump Called Hydroxychloroquine a ‘Game Changer,’ But Experts Warn Against Self-Medicating With the Drug. Here’s What You Need to Know
After President Trump, late last week, expressed great confidence in the promise of a new COVID-19 therapy that combines two existing prescription medications, supplies of these two drugs rapidly began disappearing from pharmacy shelves. The U.S. Food and Drug Administration allowed an Indian company previously restricted from importing drug products into the US to now start manufacturing one of the drugs. And U.S. plants began gearing up to produce enough to meet the surge in demand.
But in those few days, a few people who began self medicating with the drugs in an effort to prevent COVID-19 have died, and others have bee...
Source: TIME: Health - March 24, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
Is It Allergies, The Flu Or The Coronavirus? How To Tell The Difference
(CNN) — The coronavirus has infected more than 100,000 people worldwide. With all of the news of event cancellations, empty flights and health precautions (wash your hands!), it’s natural that people may get a little anxious every time they feel a tickle in their throat or the beginnings of a bad cough.
While the coronavirus is certainly something to take seriously, the chances of any individual person getting it are still low. But if you’re wondering whether that stuffy nose could end up being a worst case scenario, CNN talked to Dr. Greg Poland, a professor of medicine and Infectious diseases at the May...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - March 11, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News CNN Coronavirus Source Type: news
The Future of Flu: A Review of the Human Challenge Model and Systems Biology for Advancement of Influenza Vaccinology
Conclusions: Human challenge studies and systems biology approaches are important tools that should be used in concert to advance our understanding of influenza infection and provide targets for novel therapeutics and immunizations.
Introduction
Although influenza virus was recognized as an important pathogen over a century ago, influenza continues to cause a significant burden of disease. In the United States alone, it's estimated that in the 2017–2018 season there were 959,000 hospitalizations related to influenza illness, and 79,400 deaths (CDC, 2018). Worldwide, WHO estimates that annual influen...
Source: Frontiers in cellular and infection microbiology - April 16, 2019 Category: Microbiology Source Type: research
